CytoKinetics is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing novel muscle activators and inhibitors for the treatment of diseases of impaired muscle function. The company's vision is "empowering muscle, empowering lives" with a focus on cardiac and skeletal muscle disorders[1].
| Program | Target/Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| Aficamten (CK-037825) | Cardiac myosin inhibitor | Hypertrophic cardiomyopathy | Approved | MYQORZO™ |
| Reldesomstat (CK-2127107) | Fast skeletal muscle troponin inhibitor | ALS | Phase 3 | Clinical |
| CK-089 | Fast skeletal muscle troponin activator | Neuromuscular | Phase 1 | Active |
CytoKinetics has established strategic partnerships with major pharmaceutical companies:
Stock Ticker: CYTK (NASDAQ)
The company has maintained a strong financial position with ongoing clinical trials and recent FDA approval providing commercial revenue potential.
While primarily focused on cardiac and skeletal muscle disorders, CytoKinetics has relevance to neurodegenerative disease research through:
The company's Phase 3 program in amyotrophic lateral sclerosis (ALS) targets muscle function:
Muscle dysfunction is a significant component of several neurodegenerative diseases:
Reldesat (CK-2127107)
A fast skeletal muscle troponin activator (FSTA) designed to improve muscle function in ALS[1:1].
CK-601: Next-generation FSTA with improved pharmacokinetics
Omecamtiv mecarbil (CK-037)
Cardiac myosin activator for heart failure with reduced ejection fraction (HFrEF)[2].
CK-2127107: Being studied in pediatric SMA patients